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ABSTRACT
Objective To assess the thrombotic risk associated with
oral contraceptive use with a focus on dose of oestrogen
and type of progestogen of oral contraceptives available
in the Netherlands.
Design Population based case-control study.
Setting Six participating anticoagulation clinics in the
Netherlands (Amersfoort, Amsterdam, TheHague, Leiden,
Rotterdam, and Utrecht).
Participants Premenopausal women <50 years old who
were not pregnant, not within four weeks postpartum, and
not using a hormone excreting intrauterine device or
depot contraceptive. Analysis included 1524 patients
and 1760 controls.
Main outcome measures First objectively diagnosed
episodes of deep venous thrombosis of the leg or
pulmonary embolism. Odds ratios calculated by cross-
tabulation with a 95% confidence interval according to
Woolf’s method; adjusted odds ratios estimated by
unconditional logistic regression, standard errors derived
from the model.
Results Currently available oral contraceptives increased
the risk of venous thrombosis fivefold compared with
non-use (odds ratio 5.0, 95% CI 4.2 to 5.8). The risk
clearly differed by type of progestogen and dose of
oestrogen. The use of oral contraceptives containing
levonorgestrel was associated with an almost fourfold
increased risk of venous thrombosis (odds ratio 3.6, 2.9
to 4.6) relative to non-users, whereas the risk of venous
thrombosis compared with non-use was increased 5.6-
fold for gestodene (5.6, 3.7 to 8.4), 7.3-fold for
desogestrel (7.3, 5.3 to 10.0), 6.8-fold for cyproterone
acetate (6.8, 4.7 to 10.0), and 6.3-fold for drospirenone
(6.3, 2.9 to 13.7). The risk of venous thrombosis was
positively associated with oestrogen dose. We confirmed
ahigh risk of venous thrombosis during the firstmonths of
oral contraceptive use irrespective of the type of oral
contraceptives.
Conclusions Currently available oral contraceptives still
have a major impact on thrombosis occurrence and many
women do not use the safest brands with regard to risk of
venous thrombosis.
INTRODUCTION
The first report of an increased risk of venous throm-
bosis associated with oral contraceptives appeared in
1961.1 Since then, several large studies have confirmed
a twofold to sixfold increased risk of deep venous
thrombosis associated with current oral contraceptive
use.2-5 To decrease the risk of thrombosis, the oestro-
gen dose in combined oral contraceptiveswas stepwise
reduced over the years. A lowering of the oestrogen
dose from 100 μg to 50 μg has been associated with a
decreased risk of venous thrombosis.6-8 There is no
clear evidence that the lowering of the oestrogen dose
to 30 μg or 20 μg led to a further decrease of the risk of
deep venous thrombosis.
Oral contraceptives may contain different types of
progestogens. First generationoral contraceptives con-
tained lynestrenol, but these are now little used. Sec-
ond generation oral contraceptives, which are widely
used, contain levonorgestrel or, less often, norgestrel.
Third generation oral contraceptives, containing deso-
gestrel or gestodene, which became available in the
1980s, are also widely used. Two other types of oral
contraceptives are not included in this classification.
Preparations containing cyproterone acetate are used
for treatment of acne vulgaris, seborrhoea, or mild hir-
sutism and have anti-ovulatory action similar to that of
a progestogen.9-11 Preparations containing drospire-
none, which is an antimineralocorticoid, also inhibit
ovulation and have been on the market since
2001.12 13
Since 1995, numerous reports have been available
on the difference in thrombotic risk associated with
second and third generation oral contraceptives.4 7 14
Most reported an increased risk of venous thrombosis
associated with the newer third generation oral contra-
ceptives. Some, however, did not confirm this finding
or suggested that the risk difference between third and
second generation oral contraceptives was overesti-
mated because of bias or confounding such as referral
or prescription bias.5 15 Kemmeren et al performed a
meta-analysis on cohort and case-control studies asses-
sing the risk of venous thrombosis among women
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using oral contraceptives before 1995, and found a
twofold increased risk of venous thrombosis for third
generation oral contraceptives compared with oral
contraceptives containing levonorgestrel.16 As several
authors pointed out, none of the arguments that this
findingwas caused by bias stood up to subsequent ana-
lyses or reasoning.17-20
Oral contraceptives containing cyproterone acetate,
on the market since 1988, have been associated with a
highly increased risk of venous thrombosis in some
studies,21-23 but not all.24 25 Limited information is avail-
able for the thrombotic risk associated with the newest
oral contraceptives containing drospirenone, but a ser-
ies of reported cases of venous thrombosis after its
introduction raised concern about an increased risk
associated with this oral contraceptive.26 27 Two recent
studies sponsored by the manufacturer, however,
reported a similar thrombotic risk for drospirenone
compared with levonorgestrel.28 29 All these studies
included few cases of thrombosis and therefore had
considerable uncertainty around the risk estimates.
The aim of the present studywas to assess the throm-
botic risk associated with current oral contraceptive
use with a focus on dose of oestrogen and type of pro-
gestogen. We set out to determine which hormonal
contraceptive is safest with regard to the risk of venous
thrombosis using data from a large case-control study
of patients with a first deep venous thrombosis and
healthy controls.
METHODS
Study design
This analysis was performed using data from the
MEGA study (multiple environmental and genetic
assessment of risk factors for venous thrombosis-
study), a large, population based, case-control study
on risk factors for venous thrombosis.
BetweenMarch 1999 andSeptember 2004, consecu-
tive patients aged<70 years with a first episode of deep
venous thrombosis (leg or arm) or pulmonary embo-
lism were included from the files of six participating
anticoagulation clinics in the Netherlands (Amers-
foort, Amsterdam, The Hague, Leiden, Rotterdam,
andUtrecht). Information on the diagnostic procedure
was obtained from hospital records and general practi-
tioners.A deep venous thrombosiswas confirmedwith
Doppler ultrasonography. A pulmonary embolism
was confirmed by a ventilation perfusion lung scan,
spiral computed tomography, or angiogram. Exclu-
sion criteria were severe psychiatric problems and the
inability to speak Dutch. Of the 6567 eligible patients,
310 died soon after the venous thrombosis. Of the
remaining 6257 patients, 5184 participated (83%). Of
the non-participants, 86 were in the end stage of fatal
disease and 987 refused to participate or could not be
located. Of the participants, 4752 (91.7%) returned a
full questionnaire and 431 completed a short question-
naire by telephone.
Partners of patients <70 years old were invited to
participate as controls. Of the 5184 participating
patients, 3735 had an eligible partner. One partner
died soon after the request for participation. Of the
remaining 3734 partners, 3039 participated (81.4%).
Of the non-participants, 20 were in the end stage of
disease and 675 refused to participate or could not be
located.A full questionnairewas returned by 2873 par-
ticipating partners (94.5%), and 164 completed a short
questionnaire by phone.
From January 2002 until September 2004, addi-
tional controls were recruited by randomdigit dialling.
Phone numberswere dialled at randomwithin the geo-
graphical inclusion area of the patients. The random
controls were frequency matched to the patients with
respect to age and sex. Only controls between the ages
of 18 and 70 years with no history of deep venous
thrombosis were included and the same exclusion cri-
teria were applied as for the patients.
Of the 4350 eligible random controls, four died
before they were able to participate. Of the remaining
4346 individuals, 3000 participated (69%). Of the non-
participants, 15 were in the end stage of disease and
1331 refused to participate or could not be located. A
questionnaire was returned by 2788 (93%) of the parti-
cipating random controls.
For the current analyses, only women aged
18-50 years were included. Women who were post-
menopausal, pregnant, or within 4 weeks postpartum
at the time of the thrombotic event or index date (see
below) and women using hormonal contraception
other than oral contraceptives were excluded. From
the total patient group, we included 1524 female
patients. From the partner control group, we included
712 female partner controls. From the random digit
dialling control group, we selected 1048 female con-
trols. Of the total control group described in the cur-
rent study (n=1760), 40.5% were partner controls and
59.5%were randomdigit dialling controls. For the ana-
lyses described in this manuscript, we pooled the two
control groups into a single group and adjusted for
inclusion date.
Data collection
All participants filled in a standardised questionnaire
on risk factors for venous thrombosis such as family
history of thrombosis, pregnancy, and oral contracep-
tive use in the year before the index date. The index
date was the date of the thrombotic event for patients
and their partners and the date of filling in the ques-
tionnaire for the random controls. The questionnaire
was sent to all patients and their partners within a few
weeks after the index date. For the random controls,
the questionnaire was sent after their agreement to par-
ticipate.
At least three months after discontinuation of the
oral anticoagulation therapy, patients and their part-
ners were invited to the anticoagulation clinic for a
blood sample and an interview. During the interviews
(in person or by telephone), details on current oral con-
traceptive use were verified.
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Statistical analysis
Relative risks were assessed by calculating odds ratios
and 95% confidence intervals. Risk estimates were
adjusted by unconditional logistic regression, and con-
fidence intervals were derived from the model. The
odds ratios in the overall analysis of the risk associated
with current oral contraceptive use were adjusted for
age. When analysing the thrombotic risk associated
with dose of oestrogen or type of progestogen, an addi-
tional adjustment was made for date of inclusion
(divided in a total of 12 periods of 6 calendar months
spanning 1999-2004). For levonorgestrel, gestodene,
desogestrel, and lynestrenol, preparations can contain
different doses of oestrogen and analysis was restricted
to one dose—themost frequently used of 30 μg ethinyl-
oestradiol for levonorgestrel, gestodene, and desoges-
trel and 37.5 μg ethinyloestradiol for lynestrenol. In all
analyses, we pooled the two control groups into one
group and adjusted for inclusion date. For current
oral contraceptive use, the risk of venous thrombosis
was calculated for all users of oral contraceptives, and
separately for the different types of oral contraceptives,
compared with non-users (never users and past users
combined). Because a positive family history of venous
thrombosis has been hypothesised to lead to preferen-
tial prescription of specific types of oral contraceptive,
we took a positive family history into account. A posi-
tive family history was defined as a participant having
at least one parent or sibling with a history of venous
thrombosis as reported by the participants. Body mass
index (weight (kg)/(height (m)2)), also a potential con-
founder in the association between different types of
oral contraceptives and the risk of venous thrombosis,
was calculated using weight and height as stated by the
participants in the questionnaire. Smokingwas defined
as current smoking (comparedwith never smokers and
past smokers combined).
All oral contraceptives were classified according to
the dose of oestrogen and the type of progestogen.
Comparisons were made relative to non-users, and
between users of oral contraceptives containing differ-
ent oestrogen doses and progestogen types. Because
some combinations of oestrogendose andprogestogen
type do not exist or were not used in this study popula-
tion, we also performed stratified analyses, such as a
comparison between several types of progestogens
with the same dose of oestrogen (30 μg ethinylestra-
diol) and the effect of oestrogen dose stratified for the
different types of progestogens.
RESULTS
Table 1 shows the general characteristics of the study
population. Of all 1524 patients, 859 (56.4%) had a
deep venous thrombosis of the leg, 495 (32.5%) had a
pulmonary embolism, 111 (7.3%) had both, and 59
(3.9%) had a deep venous thrombosis of the arm. The
mean age of the 1524 patients was 37.1 years, ranging
from 18 to 49. The mean age of the 1760 controls was
similar to that of patients—namely, 37.4 years (range
18-49). Among the controls, women who were using
hormonal contraceptives (mean age 33.6) were about
six years younger thanwomenwhodid not use hormo-
nal contraceptives (mean age 39.6, mean difference
6.0, 95% CI 5.3 to 6.8).
Of the 1524 patients, 1103 (72.4%) were using oral
contraceptives at the time of thrombosis, compared
with 658/1760 (37.4%) of the controls. The percentage
of women using oral contraceptives was higher in
younger women than in older women (table 1).
Overall, current oral contraceptive use was asso-
ciated with a fivefold increased risk of venous throm-
bosis (odds ratio 5.0, 95% CI 4.2 to 5.8). Additional
adjustment for smoking and body mass index resulted
in a relative risk of 5.4 (95% CI 4.5 to 6.4). Restriction
to individuals without a positive family history of
venous thrombosis resulted in a relative risk of 5.8
(4.7 to 7.2) for all oral contraceptive users combined
versus non-users.
To show the absolute effect of oral contraceptive use
among women in different age categories, we esti-
mated the incidence of venous thrombosis in women
not using oral contraceptives aged <30 years,
30-40 years, and 40-50 years old. The overall incidence
of venous thrombosis per age category (I) can be calcu-
lated as I=(p0×I0)+(p1×I1), relative risk=I1/I0, and
Table 1 | General characteristics of study population. Data are number (%) unless otherwise
indicated
Thrombosis patients (n=1524) Controls (n=1760)
Deep venous thrombosis of leg only 859 (56.4) —
Pulmonary embolism only 495 (32.5) —
Deep venous thrombosis of leg + pulmonary
embolism
111 (7.3) —
Deep venous thrombosis of arm 59 (3.9) —
Mean (range) age (years) 37.1 (18-49) 37.4 (18-49)
Oral contraceptive use 1103 (72.4) 658 (37.4)
Oral contraceptive use by age:
<30 years 327 (87.2) 266 (68.0)
30-40 years 346 (73.0) 210 (35.5)
40-50 years 430 (63.7) 182 (23.4)
Mean (range) body mass index* 26.8 (16.0-57.8) 24.4 (15.7-50.7)
Positive family history† 309 (26.4) 186 (14.3)
Smoking‡ 380 (26.8) 500 (30.9)
*Data available for 1391 (91.3%) patients and 1591 (90.4%) controls.
†Defined as having one or more parents or siblings who experienced deep venous thrombosis or pulmonary
embolism; information about family history of venous thrombosis available for 1171 (76.8%) patients and 1298
(73.8%) controls.
‡Defined as current smoking at index date; information on smoking available for 1418 patients (93.0%) and
1618 controls (91.9%).
Table 2 | Absolute risk of venous thrombosis associated with oral contraceptive use by age
category
Age category
Incidence of venous
thrombosis in non-users of
oral contraceptives (I
0
) per
10 000 person-years*
Relative risk (95% CI) of
oral contraceptive use†
Incidence of venous
thrombosis in oral
contraceptive users (I
1
) per
10 000 person-years‡
<30 years 1.2 3.1 (2.2 to 4.6) 3.7
30-40 years 2.0 5.0 (3.8 to 6.5) 10.0
40-50 years 2.3 5.8 (4.6 to 7.3) 13.3
*I0 is based on incidences published by Naess et al.
30
†Non-users of oral contraceptives are used as the reference category.
‡I1=I0×relative risk.
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p1=1−p0, where I1=incidence of venous thrombosis in
oral contraceptive users, I0=incidence of venous
thrombosis in non-users, p1=prevalence of exposure
to oral contraceptives in the general population,
and p0=prevalence of non-exposure in the general
population.
From the distribution of oral contraceptive use in the
control group, we estimate p1 and p0. From our data, we
have estimated the relative risk of venous thrombosis
associated with current oral contraceptive use by age
category.Using this information, togetherwith the over-
all incidences of venous thrombosis in women by age
category reported by Naess et al,30 we were able to esti-
mate the absolute risk of venous thrombosis in women
not using oral contraceptives by age category separately
(table 2). Both the relative risk and absolute risk of
venous thrombosis in women not using oral contracep-
tives increase with age, which indicates that the absolute
risk of venous thrombosis associated with oral contra-
ceptive use increases with age.
Most women used a monophasic oral contraceptive,
but triphasic oral contraceptives were also used. Eighty
nine patients and 72 controls were using a triphasic oral
contraceptive containing levonorgestrel with 30-40 μg
ethinylestradiol. The risk of venous thrombosis with
this triphasic pill was similar to that with monophasic
oral contraceptives that contained levonorgestrel and
30 μg ethinylestradiol (odds ratio 1.0, 95% CI 0.7 to
1.4); triphasic oral contraceptives increased the risk rela-
tive to non-users to the same extent asmonophasic com-
binedcontraceptives. The riskofvenous thrombosiswas
also similar for triphasic and monophasic preparations
containing gestodene, although the number of users of a
triphasic preparation was small (four patients and five
controls).
Progestogen-only oral contraceptives were used by
only two patients (lynestrenol) and four controls (des-
ogestrel). No risk estimates can be inferred from these
small numbers.
Oestrogen dose and type of progestogen in combined oral
contraceptives
Table 3 and the figure show the risk of venous throm-
bosis associated with combined oral contraceptives
containing different types of progestogens.
Oral contraceptives containing levonorgestrel were
the most frequently used oral contraceptives in the
control group (57.0% of all users). Among the throm-
bosis patients the most frequently used oral contracep-
tives contained either levonorgestrel (44% of all users)
or desogestrel (26.2%).
Compared with non-use, use of oral contraceptives
was associated with increased risk of venous thrombo-
sis—almost fourfold increase for contraceptives con-
taining levonorgestrel (odds ratio 3.6, 95% CI 2.9 to
4.6), 5.6-fold (95% CI 3.7 to 8.4) for those containing
gestodene, 7.3-fold (5.3 to 10.0) for desogestrel, 6.8-
fold (4.7 to 10.0) for cyproterone acetate, and 6.3-fold
(2.9 to 13.7) for drospirenone.
When we directly compared different types of oral
contraceptives with those containing levonorgestrel
(the most frequently used progestogen), we found an
increased risk of thrombosis associatedwith those con-
taining gestodene (odds ratio 1.6, 95% CI 1.0 to 2.4),
desogestrel (2.0, 1.4 to 2.8), cyproterone acetate (2.0,
1.3 to 3.0), and drospirenone (1.7, 0.7 to 3.9). Among
users of third generation oral contraceptives, the
thrombotic risk for contraceptives containing desoges-
trel was mildly increased compared with oral contra-
ceptives containing gestodene (1.3, 0.8 to 2.2).
To assess the risk of venous thrombosis associated
with the dose of oestrogen, we restricted the analysis
to monophasic preparations with levonorgestrel, ges-
todene, or desogestrel.With anoestrogendose of 30μg
as the reference category, the thrombotic risk was 0.8
(95% CI 0.5 to 1.2) for an oestrogen dose of 20 μg and
1.9 (1.1 to 3.4) for a dose of 50 μg.
In table 4 the risk of venous thrombosis associated
with different doses of oestrogen are presented by type
of progestogen of the most frequently used combined
oral contraceptives (monophasic)—that is, levonorges-
trel, gestodene, and desogestrel. The oestrogen dose
was positively associated with the risk of venous throm-
bosis for preparations containing desogestrel and those
containing gestodene. Using the most commonly used
Table 3 | Risk of venous thrombosis associated with different types of progestogens in
combined oral preparations. Data are numbers (percentages) unless stated otherwise
Type of progestogen
Thrombosis patients
(n=1524) Controls (n=1760) Odds ratio (95% CI)*
Levonorgestrel† 485 (31.9) 373 (21.2) 3.6 (2.9 to 4.6)
Gestodene† 119 (7.8) 67 (3.8) 5.6 (3.7 to 8.4)
Desogestrel† 289 (19.0) 108 (6.2) 7.3 (5.3 to 10.0)
Lynestrenol† 44 (2.9) 19 (1.1) 5.6 (3.0 to 10.2)
Norethisterone 11 (0.7) 7 (0.4) 3.9 (1.4 to 10.6)
Cyproterone acetate 125 (8.2) 62 (3.5) 6.8 (4.7 to 10.0)
Norgestimate 9 (0.6) 4 (0.2) 5.9 (1.7 to 21.0)
Drospirenone 19 (1.2) 14 (0.8) 6.3 (2.9 to 13.7)
No oral contraceptive
(reference)
421 (27.7) 1102 (62.8) 1
*Odds ratio adjusted for age and period of inclusion (categorical; divided per 6 calendar months).
†Analysis restricted to preparation with most commonly used dose of oestrogen: for levonorgestrel, gestodene,
and desogestrel, 30 μg (645 patients and 385 controls); for lynestrenol 37.5 μg (42 patients and 19 controls).
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oestrogen dose (30 μg) as the reference category, we
found oral contraceptives containing 20 μg estradiol
were associated with a decreased risk of thrombosis
whereas those containing 50 μg estradiolwere associated
with an increased risk of thrombosis. For contraceptives
containing levonorgestrel, no reduced thrombotic risk
was seen for those containing20μgethinylestradiol com-
pared with 30 μg ethinylestradiol, but very few women
used an oral contraceptive containing levonorgestrel
combined with 20 μg ethinylestradiol, as shown by the
wide confidence interval.
Risk associated with oral contraceptive use for different
types of thrombosis
The risk of venous thrombosis associated with current
oral contraceptive use was increased for deep venous
thrombosis of the leg and pulmonary embolism
(table 5). The relative risk was higher for women
with a deep venous thrombosis of the leg (odds ratio
6.6, 95%CI 5.4 to 8.0) than for women with a pulmon-
ary embolism (with or without deep venous thrombo-
sis of the leg) (odds ratio 3.9, 3.2 to 4.8). The risk
differences between types of progestogens which we
observed for all types of thromboses combined
remained essentially the same for both types of throm-
bosis separately.
Current oral contraceptive use was also associated
with a twofold increased risk of deep venous thrombo-
sis of the arm (odds ratio 1.9, 95%CI 1.1 to 3.4), but the
number of patients with this thrombosis was too small
to estimate the risk of venous thrombosis associated
with different types of progestogens.
Duration of oral contraceptive use
For 1005 patients with venous thrombosis and 533
control subjects information on the duration of oral
contraceptive use on the index date was available.
The risk of venous thrombosis was clearly highest dur-
ing the first three months of use (odds ratio 12.6, 95%
CI 7.1 to 22.4) (table 6). After one year, the risk of
venous thrombosis for oral contraceptive users com-
pared with non-users decreased to the overall estimate
of a fivefold increased risk. In all time intervals, includ-
ing those of prolonged use, both second and third gen-
eration oral contraceptives were used. When we
restricted the analysis to women who were using oral
contraceptives formore than two years, the thrombotic
risk with oral contraceptives containing desogestrel
remained increased compared with those containing
levonorgestrel and was similar to the overall risk—for
gestodene odds ratio 1.5 (95% CI 0.9 to 2.6) and for
desogestrel 1.9 (1.3 to 2.9).
For the newest types of oral contraceptives, we also
assessed the risk of thrombosis restricted to short term
users, to account for attrition of susceptibles (women at
increased risk of getting deep venous thrombosis). The
number of short term users for an individual type of
progestogen was low, resulting in wide confidence
intervals. However, for women using oral contracep-
tives for three months or less, the results support an
increased risk for both drospirenone (odds ratio 1.9,
95% CI 0.2 to 21.3) and cyproterone acetate (1.6, 0.3
to 9.9) compared with oral contraceptives containing
levonorgestrel.
Table 5 | Risk of different types of venous thrombosis associated with oral contraceptive use by different type of
progestogen. Patients with venous thrombosis of the arm omitted from this analysis
Type of progestogen No of controls
Deep venous thrombosis of leg Pulmonary embolism*
No of patients Odds ratio (95% CI)† No of patients Odds ratio (95% CI)†
All 654 661 6.6 (5.4 to 8.0) 407 3.9 (3.2 to 4.8)
Levonorgestrel‡ 373 300 5.0 (3.8 to 6.5) 171 2.8 (2.1 to 3.8)
Gestodene‡ 67 74 8.1 (5.2 to 12.7) 43 3.8 2.2 to 6.3)
Desogestrel‡ 108 159 8.7 (6.1 to 12.4) 122 7.1 (4.9 to 10.4)
Lynestrenol‡ 19 27 7.3 (3.7 to 14.2) 15 4.5 (2.1 to 9.6)
Norethisterone 7 7 5.4 (1.8 to 16.6) 4 3.1 (0.8 to 11.5)
Cyproterone acetate 62 77 9.4 (6.1 to 14.3) 41 5.6 (3.4 to 9.2)
Norgestimate 4 5 8.7 (2.1 to 35.5) 4 5.2 (1.1 to 23.7)
Drospirenone 14 12 9.1 (3.9 to 21.5) 7 6.2 (2.2 to 17.6)
No oral contraceptive
(reference)
1102 197 1 198 1
*With or without deep venous thrombosis.
†Odds ratio per type of progestogen adjusted for age and period of inclusion (categorical; divided per 6 calendar months).
‡Analysis restricted to preparation with most commonly used dose of oestrogen. For levonorgestrel, gestodene, and desogestrel, this was 30 μg (388
patients with deep venous thrombosis of the leg, 242 patients with pulmonary embolism, and 385 controls). For lynestrenol, this was 37.5 μg (25
patients with deep venous thrombosis of the leg, 15 with pulmonary embolism, and 19 controls).
Table 4 | The risk of venous thrombosis associated with different doses of ethinylestradiol in
monophasic oral contraceptives. Data are odds ratios adjusted for age (95% CI) unless
stated otherwise
Ethinylestradiol
dose (μg)
Percentage use
among controls* Levonorgestrel Gestodene Desogestrel
20 11.2 1.1 (0.4 to 3.1) 0.3 (0.2 to 0.7) 0.7 (0.4 to 1.2)
30† 84.4 1 1 1
50 4.4 2.2 (1.3 to 3.7) — —
*In total, 51 women used a monophasic preparation with 20 μg ethinylestradiol, 385 women used one with
30 μg, and 20 used one with 50 μg (total 456).
†Reference category is the most commonly used dose of oestrogen among controls.
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DISCUSSION
Principal findings of the study
We found that currently available oral contraceptives
were associatedwith a fivefold increased risk of venous
thrombosis. This result confirms the results of previous
studies reporting a twofold to sixfold increased risk of
deep venous thrombosis associated with oral contra-
ceptive use.2-5 Several older studies report a slightly
lower risk, which is probably because nowadays differ-
ent types of oral contraceptives containing newer pro-
gestogens with higher risks are being used. The risk
clearly differed by type of progestogen and dose of oes-
trogen. Oral contraceptives containing desogestrel
were associatedwith a twofold increased risk of venous
thrombosis compared with oral contraceptives con-
taining levonorgestrel, which persisted among
women who had used these oral contraceptives for
many years.
The risk of thrombosis associated with oral contra-
ceptives containing cyproterone acetate or drospire-
none was similar to that associated with oral
contraceptives containing desogestrel—a sixfold to
sevenfold increased risk compared with non-users.
Comparison with other studies
In contrast to our findings, a large prospective cohort
study found an equal risk of thrombosis associatedwith
oral contraceptives containing drospirenone or
levonorgestrel.28 However, our results of an excess
risk for drospirenone are supported by previous data
from laboratory studies in healthy users, where an
excess in thrombin generation (endogenous thrombin
potential) was found for oral contraceptives containing
desogestrel, cyproterone acetate, and drospirenone
that exceeded the effect of oral contraceptives contain-
ing levonorgestrel.31 Previous studies have also shown
that this global test predicts risk of thrombosis, even in
women not using the pill and in men.32
The size of our study allowed separate risk estima-
tion for both desogestrel and gestodene, whereas most
previous studies either included only one type or
grouped these two progestogens together. The risk of
deep venous thrombosis with oral contraceptives
containing desogestrel was slightly higher than that
with oral contraceptives containing gestodene (odds
ratio 1.3, 95% CI 0.8 to 2.2). This confirmed the find-
ings of a previous case-control study of oral contracep-
tives containing gestodene or desogestrel.24
Furthermore, oral contraceptives containing desoges-
trel have been associatedwith amore pronounced acti-
vated protein C resistance and higher levels of sex
hormone binding globulin than those containing ges-
todene, which are likely to indicate thrombotic risk.33
Results of a crossover study in healthy users, including
33women, showed different effects on the haemostatic
system for third and second generation oral
contraceptives.34 35Oral contraceptives containingdes-
ogestrel were associated with more pronounced
changes in both the procoagulation and anti-
coagulation systems compared with oral contracep-
tives containing levonorgestrel and activated protein
C resistance (in both the activated partial thromboplas-
tin time as well as the endogenous thrombin potential
test) was more pronounced.34-36
We found the risk of venous thrombosis was posi-
tively associated with oestrogen dose. Lidegaard et al
also showed a positive association between oestrogen
dose and the risk of venous thrombosis for oral contra-
ceptives with oestrogen doses lower than 50 μg.24 The
same trend was shown earlier for oral contraceptives
with higher doses of oestrogen (50-100 μg).6-8
Strengths and limitations of this study
This studywas performedmore than a decade after the
introduction of oral contraceptives containing deso-
gestrel or gestodene in the Netherlands, and data
were collected 10 years after those that led to our first
report on the increased thrombogeneity of third gen-
eration progestogens. Some women have used oral
contraceptives containing desogestrel or gestodene
for a considerable time. The large study size allowed
us to study the duration of oral contraceptive use in
detail. Clearly the risk of thrombosis was highest in
the first year of oral contraceptive use, with a peak in
the first three months of use (odds ratio 12.6, 95% CI
7.1 to 22.4). This high risk of venous thrombosis during
Table 6 | Risk of venous thrombosis associated with duration of use of oral contraceptive. Data are number
Duration of use (months)*
No of thrombosis patients
No of controls Odds ratio (95% CI)†Total Using levonorgestrel
Using
gestodene
Using
desogestrel
≤3 66 32 8 10 15 12.6 (7.1 to 22.4)
>3 and ≤6 49 19 7 9 17 8.3 (4.7 to 14.5)
>6 and ≤12 63 31 4 9 26 7.5 (4.7 to 12.2)
>12 and ≤24 75 35 5 17 46 5.0 (3.4 to 7.4)
>24 and ≤60 141 77 15 31 87 5.0 (3.7 to 6.8)
>60 611 251 68 179 342 5.2 (4.3 to 6.2)
No oral contraceptive
(reference)
421 — — — 1102 1
*Duration of oral contraceptive use defined as time since start date of last oral contraceptive used before index date for women who used oral
contraceptives at the time of the index date. For 221 users (98 patients and 125 controls) duration of use was unknown.
†Odds ratio adjusted for age.
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the first months of oral contraceptive use was not the
result of differences in the type of oral contraceptives,
norwas the high risk conferred by third generationoral
contraceptives or oral contraceptives containing
cyproterone acetate the result of recent use of particu-
lar brands (“attrition of susceptibles”). We confirmed
the latter in an analysis limited towomenwhohad used
oral contraceptives for more than two years. These
results clearly indicate that “recent introduction” bias
cannot have affected our results. Oral contraceptives
containing drospirenone have been available in the
Netherlands since 2002. Here we countered potential
“recent introduction” bias by restricting the analysis to
short termusers, andwe still found a similar excess risk
in comparison with short term use of oral contracep-
tives containing levonorgestrel (1.6-fold increased risk
for drospirenone).
The relative risk associated with oral contraceptive
use was higher for deep venous thrombosis of the leg
than for pulmonary embolism. Oral contraceptive use
was also associated with a twofold increased risk of a
deep venous thrombosis of the arm, as previously
reported from this study.37
It could be argued that recall bias may have occurred
in our study. However, patients fill in the questionnaire
within a few weeks after the thrombotic event. For con-
trols, current use of oral contraceptives is filled in on the
questionnaire. The short time between thrombosis and
filling in the questionnaire, as well as the fact that the
questionnaire is sent to the participants’ home, where
the package of the oral contraceptive is readily available,
makes the occurrence of recall bias very unlikely.
Conclusions and policy implications
All currentlyusedoral contraceptives are equally effec-
tive in preventing pregnancy. However, especially the
preparations containing cyproterone acetate or dros-
pirenone also have other indications, such as treatment
of acne vulgaris, seborrhoea, or mild hirsutism. A
recent Cochrane review assessed the effect of different
combined oral contraceptives for the treatment of
acne.38 It concluded that only minor differences were
found in the effectiveness of preparations containing
cyproterone acetate, desogestrel, or levonorgestrel in
the treatment of acne. Also with regard to weight gain
while using oral contraceptives, no major differences
were found between preparations containing drospir-
enone or levonorgestrel.39 The effectiveness of allevia-
tion of premenstrual symptoms by oral contraceptives
containing drospirenone compared with placebo or
other oral contraceptives has not been
demonstrated.40
Thus, available evidence suggests that, even for acne
or weight gain, there is no clear difference between
most commonly used oral contraceptives. This indi-
cates that the choice of oral contraceptive should be
based on the smallest increase of side effects, such as
risk of venous thrombosis. It is estimated that 100 mil-
lion women use an oral contraceptive worldwide.41
With such a large number of women using oral contra-
ceptives, even the smallest increase of side effects will
affect many. Knowledge of these risks and efforts to
reduce them are of crucial importance. Our results
clearly show that the safest option with regard to the
risk of venous thrombosis is an oral contraceptive con-
taining levonorgestrel combined with a low dose of
oestrogen.
We thank the directors of the Anticoagulation Clinics of Amersfoort (MHH
Kramer), Amsterdam (M Remkes), Leiden (FJM van der Meer), The Hague
(E van Meegen), Rotterdam (AAH Kasbergen), and Utrecht (J de Vries-
Goldschmeding) who made the recruitment of patients possible. The
interviewers (JCM van den Berg, B Berbee, S van der Leden, M Roosen,
and EC Willems of Brilman) performed the blood draws. We also thank I
de Jonge, R Roelofsen, M Streevelaar, LMJ Timmers, and JJ Schreijer for
their administrative support and data management. The fellows
ID Bezemer, JW Blom, ER Pomp, KJ van Stralen, LW Tick took part in every
step of the data collection. We express our gratitude to all individuals who
participated in the MEGA study.
Funding: This research was supported by the Netherlands Heart
Foundation (NHS 98.113), the Dutch Cancer Foundation (RUL 99/1992)
and the Netherlands Organisation for Scientific Research (912-03-033|
2003). The funding organisations did not play a role in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; preparation, review, or approval of the
manuscript.
Competing interests: None declared
Ethical approval: All participants gave written informed consent. The
study was approved by the Medical Ethics Committee of the Leiden
University Medical Center, Leiden, the Netherlands.
1 Jordan WM. Pulmonary embolism. Lancet 1961;1146-7.
2 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM,
Rosendaal FR. Increased risk of venous thrombosis in oral-
contraceptive users who are carriers of factor V Leiden mutation.
Lancet 1994;344:1453-7.
3 Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal
venous thromboembolism in youngwomen: a case-control study. Int
J Epidemiol 1992;21:48-52.
4 WHO. Venous thromboembolic disease and combined oral
contraceptives: results of international multicentre case-control
study. World Health Organization Collaborative Study of
Cardiovascular Disease and Steroid Hormone Contraception. Lancet
1995;346:1575-82.
5 Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
Population-based study of risk of venous thromboembolism
associated with various oral contraceptives. Lancet 1997;349:83-8.
6 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and
venous thromboembolism: findings in a large prospective study.BMJ
1986;292:526.
7 Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR,
Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk
of deep-vein thrombosis associated with oral contraceptives
containing a third-generation progestagen. Lancet
1995;346:1593-6.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Current oral contraceptive use is associated with a twofold to sixfold increased risk of venous
thrombosis
Limited information is available on the risk associated with the newest type of oral
contraceptives containing drospirenone
WHAT THIS STUDY ADDS
The venous thrombotic risk clearly differed by type of progestogen and was positively
associated with dose of oestrogen
The risk of thrombosis associated with oral contraceptives containing cyproterone acetate or
drospirenone was similar to that associated with oral contraceptives containing desogestrel;
a sixfold to sevenfold increased risk compared with non-users
The safest option with regard to the risk of venous thrombosis is an oral contraceptive
containing levonorgestrel combined with a low dose of oestrogen
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 8
8 Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV,
Lundin FE. Oral contraceptive estrogen dose and the risk of deep
venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
9 Van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C,
Heithecker R. The effect of 2 combined oral contraceptives
containing either drospirenone or cyproterone acetate on acne and
seborrhea. Cutis 2002;69:2-15.
10 KuhnzW, Staks T, JuttingG. Pharmacokinetics of cyproterone acetate
and ethinylestradiol in 15 women who received a combination oral
contraceptive during three treatment cycles. Contraception
1993;48:557-75.
11 Lachnit-Fixson U. The development and evaluation of an ovulation
inhibitor (DIAne) containing an antiandrogen. Acta Obstet Gynecol
Scand Suppl 1979;88:33-42.
12 Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E.
Drospirenone: a novel progestogen with antimineralocorticoid and
antiandrogenic activity. Ann N Y Acad Sci 1995;761:311-35.
13 Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects
of a new oral contraceptive containing an antimineralocorticoid
progestogen, drospirenone, on the renin-aldosterone system, body
weight, blood pressure, glucose tolerance, and lipid metabolism. J
Clin Endocrinol Metab 1995;80:1816-21.
14 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic
cardiovascular death and nonfatal venous thromboembolism in
women using oral contraceptives with differing progestagen
components. Lancet 1995;346:1589-93.
15 Lidegaard O, EdströmB, Kreiner S. Oral contraceptives and venous
thromboembolism. A case-control study. Contraception
1998;57:291-301.
16 Kemmeren JM, Algra A, Grobbee DE. Third generation oral
contraceptives and risk of venous thrombosis: meta-analysis. BMJ
2001;323:131-4.
17 Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW,
Rosendaal FR. Third-generation oral contraceptive and deep venous
thrombosis: from epidemiologic controversy to new insight in
coagulation. Am J Obstet Gynecol 1997;177:887-91.
18 Walker AM. Newer oral contraceptives and the risk of venous
thromboembolism. Contraception 1998;57:169-81.
19 Bloemenkamp KW, Rosendaal FR, Büller HR, Helmerhorst FM,
Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of
current low-dose oral contraceptives is not explained by diagnostic
suspicion and referral bias. Arch Intern Med 1999;159:65-70.
20 Farley TM, Meirik O, Collins J. Cardiovascular disease and combined
oral contraceptives: reviewing the evidence and balancing the risks.
Hum Reprod Update 1999;5:721-35.
21 WHO. Effect of different progestagens in low oestrogen oral
contraceptives on venous thromboembolic disease. World Health
Organization Collaborative Study of Cardiovascular Disease and
Steroid Hormone Contraception. Lancet 1995;346:1582-8.
22 Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism
with cyproterone or levonorgestrel contraceptives. Lancet
2001;358:1427-9.
23 Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral
contraceptives and fatal pulmonary embolism. Lancet
2000;355:2133-4.
24 Lidegaard O, EdströmB, Kreiner S. Oral contraceptives and venous
thromboembolism: a five-year national case-control study.
Contraception 2002;65:187-96.
25 Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism
associated with cyproterone acetate in combination with
ethinyloestradiol (Dianette): observational studies using the UK
General Practice Research Database. Pharmacoepidemiol Drug Saf
2004;13:427-36.
26 Van Grootheest K, Vrieling T. Thromboembolism associated with the
new contraceptive Yasmin. BMJ 2003;326:257.
27 Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ
2002;324:869.
28 Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a
drospirenone-containing oral contraceptive: final results from the
European Active Surveillance Study on oral contraceptives based on
142,475 women-years of observation. Contraception
2007;75:344-54.
29 Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk
of thromboembolism in women taking ethinylestradiol/
drospirenone and other oral contraceptives.Obstet Gynecol
2007;110:587-93.
30 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC,
Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous
thrombosis: a population-based study. J Thromb Haemost
2007;5:692-9.
31 Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR.
Prothrombotic changes in users of combined oral contraceptives
containingdrospirenoneandcyproteroneacetate. J ThrombHaemost
2004;2:2060-2.
32 Tans G, van Hylckama Vlieg A, Thomassen MCLGD, Curvers J,
Bertina RM, Rosing J, et al. Activated protein C resistance determined
with a thrombin generation-based test predicts for venous
thrombosis in men and women. Br J Haematol 2003;122:465-70.
33 van Vliet HA, Frolich M, Christella M, Thomassen MCLGD, Doggen
CJM, Rosendaal FR, et al. Association between sex hormone-binding
globulin levels and activated protein C resistance in explaining the
risk of thrombosis in users of oral contraceptives containing different
progestogens. Hum Reprod 2005;20:563-8.
34 Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JC,
Prins MH, et al. A randomized cross-over study on the effects of
levonorgestrel- and desogestrel-containing oral contraceptives on
the anticoagulant pathways. Thromb Haemost 2000;84:15-21.
35 Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN,
Tans G, et al. Effects on coagulation of levonorgestrel- and
desogestrel-containing low dose oral contraceptives: a cross-over
study. Thromb Haemost 2000;84:4-8.
36 Kemmeren JM, Algra A,Meijers JC, BoumaBN, Grobbee DE. Effects of
second and third generation oral contraceptives and their respective
progestagens on the coagulation system in the absence or presence
of the factor V Leidenmutation. ThrombHaemost 2002;87:199-205.
37 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk
factors for upper extremity deep venous thrombosis. J Thromb
Haemost 2005;3:2471-8.
38 Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined
oral contraceptive pills for treatment of acne. Cochrane Database
Syst Rev 2007;(3):CD004425.
39 Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM.
Combination contraceptives: effects on weight. Cochrane Database
Syst Rev 2008;(4):CD003987.
40 Lopez LM, KapteinA,Helmerhorst FM.Oral contraceptives containing
drospirenone for premenstrual syndrome. Cochrane Database Syst
Rev 2009;(2):CD006586.
41 World Health Organization. Cardiovascular disease and steroid
hormone contraception. Report of a WHO Technical Report Series
877. Geneva: WHO, 1998.
Accepted: 29 May 2009
RESEARCH
page 8 of 8 BMJ | ONLINE FIRST | bmj.com
